Study Phase 3

Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study

Trial Information

Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment415% Female81%% White100%
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-ALZ-302 (PMID # 19042161-CR003940)Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)84

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.